NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution

Background: In glioblastoma (GBM), tumor progression occurs mainly within the irradiated tumor volume. To address this challenge, a radiosensitization strategy with intravenous gadolinium-based theranostic nanoparticles (AGuIX) is being explored in the NANO-GBM phase1b/2R trial (NCT04881032). Here,...

Descrición completa

Detalles Bibliográficos

Principais autores:	J. Biau, X. Durando, F. Boux, I. Molnar, J. Moreau, B. Leyrat, F. Guillemin, A. Lavielle, Y. Cremillieux, K. Seddik, S. Dufort, O. De Beaumont, E. Thivat, G. Le Duc
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2024-09-01
Series:	Clinical and Translational Radiation Oncology
Assuntos:	Glioblastoma Radiotherapy Nanoparticles AGuIX
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2405630824001101
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!